Cofetuzumab pelidotin is under clinical development by Pfizer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cofetuzumab pelidotin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cofetuzumab pelidotin overview
Cofetuzumab pelidotin (PF-06647020) is under development for the treatment of solid tumors including triple negative breast cancer, ovarian cancer and non-small cell lung cancer. It is administered by intravenous route. The drug candidate is an antibody-drug conjugate comprising of a humanized monoclonal antibody directed against PTK7, linked to an auristatin microtubule inhibitor payload and a cleavable valine-citrulline linker. It is a new molecular entity.
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Cofetuzumab pelidotin’s drug-specific PTSR and LoA scores, buy the report here.